These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 27283831)
21. Smart AS1411-aptamer conjugated pegylated PAMAM dendrimer for the superior delivery of camptothecin to colon adenocarcinoma in vitro and in vivo. Alibolandi M; Taghdisi SM; Ramezani P; Hosseini Shamili F; Farzad SA; Abnous K; Ramezani M Int J Pharm; 2017 Mar; 519(1-2):352-364. PubMed ID: 28126548 [TBL] [Abstract][Full Text] [Related]
22. Overcoming multidrug resistance using liposomal epirubicin and antisense oligonucleotides targeting pump and nonpump resistances in vitro and in vivo. Lo YL; Liu Y; Tsai JC Biomed Pharmacother; 2013 May; 67(4):261-7. PubMed ID: 23540284 [TBL] [Abstract][Full Text] [Related]
23. Epithelial cell adhesion molecule aptamer conjugated PEG-PLGA nanopolymersomes for targeted delivery of doxorubicin to human breast adenocarcinoma cell line in vitro. Alibolandi M; Ramezani M; Sadeghi F; Abnous K; Hadizadeh F Int J Pharm; 2015 Feb; 479(1):241-51. PubMed ID: 25529433 [TBL] [Abstract][Full Text] [Related]
24. Enhanced theranostic efficacy of epirubicin-loaded SPION@MSN through co-delivery of an anti-miR-21-expressing plasmid and ZIF-8 hybridization to target colon adenocarcinoma. Abrishami A; Bahrami AR; Saljooghi AS; Matin MM Nanoscale; 2024 Mar; 16(12):6215-6240. PubMed ID: 38446130 [TBL] [Abstract][Full Text] [Related]
26. Double targeting, controlled release and reversible delivery of daunorubicin to cancer cells by polyvalent aptamers-modified gold nanoparticles. Taghdisi SM; Danesh NM; Lavaee P; Emrani AS; Hassanabad KY; Ramezani M; Abnous K Mater Sci Eng C Mater Biol Appl; 2016 Apr; 61():753-61. PubMed ID: 26838906 [TBL] [Abstract][Full Text] [Related]
27. Surface functionalized mesoporous silica nanoparticles as an effective carrier for epirubicin delivery to cancer cells. Hanafi-Bojd MY; Jaafari MR; Ramezanian N; Xue M; Amin M; Shahtahmassebi N; Malaekeh-Nikouei B Eur J Pharm Biopharm; 2015 Jan; 89():248-58. PubMed ID: 25511563 [TBL] [Abstract][Full Text] [Related]
28. Surface decorated nanoparticles as surrogate carriers for improved transport and absorption of epirubicin across the gastrointestinal tract: Pharmacokinetic and pharmacodynamic investigations. Tariq M; Alam MA; Singh AT; Panda AK; Talegaonkar S Int J Pharm; 2016 Mar; 501(1-2):18-31. PubMed ID: 26812610 [TBL] [Abstract][Full Text] [Related]
29. Epirubicin-loaded polymeric micelles effectively treat axillary lymph nodes metastasis of breast cancer through selective accumulation and pH-triggered drug release. Chida T; Miura Y; Cabral H; Nomoto T; Kataoka K; Nishiyama N J Control Release; 2018 Dec; 292():130-140. PubMed ID: 30391405 [TBL] [Abstract][Full Text] [Related]
30. Aptamer-nanoparticle bioconjugates enhance intracellular delivery of vinorelbine to breast cancer cells. Zhou W; Zhou Y; Wu J; Liu Z; Zhao H; Liu J; Ding J J Drug Target; 2014 Jan; 22(1):57-66. PubMed ID: 24156476 [TBL] [Abstract][Full Text] [Related]
31. Optimization of epirubicin nanoparticles using experimental design for enhanced intravesical drug delivery. Chang LC; Wu SC; Tsai JW; Yu TJ; Tsai TR Int J Pharm; 2009 Jul; 376(1-2):195-203. PubMed ID: 19439169 [TBL] [Abstract][Full Text] [Related]
32. Self-Assembled Hybrids of Fluorescent Carbon Dots and PAMAM Dendrimers for Epirubicin Delivery and Intracellular Imaging. Matai I; Sachdev A; Gopinath P ACS Appl Mater Interfaces; 2015 Jun; 7(21):11423-35. PubMed ID: 25946165 [TBL] [Abstract][Full Text] [Related]
33. Combined effect of epirubicin and lymphokine-activated killer cells on the resistant human breast cancer cells. Ozkan A; Ayhan A; Fiskin K Cell Biol Toxicol; 2004 Sep; 20(5):261-71. PubMed ID: 15685929 [TBL] [Abstract][Full Text] [Related]
34. Epirubicin loaded with propylene glycol liposomes significantly overcomes multidrug resistance in breast cancer. Zhao YZ; Dai DD; Lu CT; Chen LJ; Lin M; Shen XT; Li XK; Zhang M; Jiang X; Jin RR; Li X; Lv HF; Cai L; Huang PT Cancer Lett; 2013 Mar; 330(1):74-83. PubMed ID: 23186833 [TBL] [Abstract][Full Text] [Related]
35. EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery. Xie X; Li F; Zhang H; Lu Y; Lian S; Lin H; Gao Y; Jia L Eur J Pharm Sci; 2016 Feb; 83():28-35. PubMed ID: 26690044 [TBL] [Abstract][Full Text] [Related]
36. A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer. Haisma HJ; Boven E; van Muijen M; de Jong J; van der Vijgh WJ; Pinedo HM Br J Cancer; 1992 Sep; 66(3):474-8. PubMed ID: 1520585 [TBL] [Abstract][Full Text] [Related]
37. Polyvalent mesoporous silica nanoparticle-aptamer bioconjugates target breast cancer cells. Li LL; Yin Q; Cheng J; Lu Y Adv Healthc Mater; 2012 Sep; 1(5):567-72. PubMed ID: 23184791 [TBL] [Abstract][Full Text] [Related]
38. Improved antitumor activity of epirubicin-loaded CXCR4-targeted polymeric nanoparticles in liver cancers. Di-Wen S; Pan GZ; Hao L; Zhang J; Xue QZ; Wang P; Yuan QZ Int J Pharm; 2016 Mar; 500(1-2):54-61. PubMed ID: 26748365 [TBL] [Abstract][Full Text] [Related]
39. Lipid nanoparticle-based co-delivery of epirubicin and BCL-2 siRNA for enhanced intracellular drug release and reversing multidrug resistance. Yu M; Han S; Kou Z; Dai J; Liu J; Wei C; Li Y; Jiang L; Sun Y Artif Cells Nanomed Biotechnol; 2018 Mar; 46(2):323-332. PubMed ID: 28393563 [TBL] [Abstract][Full Text] [Related]
40. A multi-storey DNA nanostructure containing doxorubicin and AS1411 aptamer for targeting breast cancer cells. Yaghoobi E; Zavvar T; Ramezani M; Alibolandi M; Rahimzadeh Oskuei S; Zahiri M; Alinezhad Nameghi M; Abnous K; Taghdisi SM J Drug Target; 2022 Dec; 30(10):1106-1112. PubMed ID: 35736221 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]